Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Patch may boost fetal spina bifida repair, early trial hints

NCT ID NCT03794011

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two minimally invasive fetal surgery techniques for repairing neural tube defects (spina bifida) in the womb. One method uses a Durepair patch to reinforce the repair, while the other does not. Researchers aim to see if the patch leads to a thicker repair and fewer complications like spinal fluid leaks. The trial involves 38 pregnant women and is still active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Durepair patch (a collagen-based patch used during fetal surgery)
What this could lead to
If successful, this could lead to a safer, more effective fetal surgery for spina bifida, reducing complications like spinal fluid leaks and improving outcomes for babies.
What could go wrong
This is a small, early-phase trial (phase 1) with only 38 participants, so results may not apply to everyone. The surgery itself carries risks for both mother and fetus, and the patch may not provide the expected benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

38 people

The number who actually took part.

Started

Dec 2018

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pregnant women - maternal age 18 years or older and capable of consenting for their own participation in this study. 2. Singleton pregnancy. 3. MMC with the upper boundary located between T1 and S1. 4. Evidence of hindbrain herniation (confirmed on MRI to have an Arnold-Chiari type II malformation). An exception will be made for patients unable to have an MRI due to implants or any medical reasons. These patients will have the Arnold-Chiari type II malformation reviewed by ultrasonography. 5. Absence of chromosomal abnormalities and associated anomalies 6. Gestational age at the time of the procedure will be between 19 0/7 weeks and 25 6/7 weeks. 7. Normal karyotype and/or normal chromosomal microarray (CMA) by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). If there is a balanced translocation with normal CMA with no other anomalies the candidate can be included. Patients declining invasive testing will be excluded. Results by flouorescence in situ hybridization (FISH) will be acceptable if the patient is at 24 weeks or more. 8. The family has considered and declined the option of termination of the pregnancy at less than 24 weeks. 9. The family meets psychosocial criteria (sufficient social support, ability to understand the requirements of the study). 10. Parental/guardian permission (informed consent) for follow up of the child after birth. 11. For totally percutaneous expandable port assisted cases: Appropriate anterior window on the uterus free of placental tissue, as assessed by ultrasound, such that direct access to the fetus through the maternal abdominal wall is possible. If this criteria is not met, patient may still be eligible for laparotomy assisted fetoscopic repair if all other inclusion criteria and no exclusion criteria are met. Exclusion Criteria: 1. Fetal anomaly unrelated to MMC. 2. Severe kyphosis. 3. Increased risk for preterm labor including short cervical length (\<1.5 cm), history of incompetent cervix with or without cerclage, and previous preterm birth. 4. Placental abnormalities (previa, abruption, accreta) known at time of enrollment. 5. A pre-pregnancy body-mass index ≥40. 6. Contraindications to surgery including previous hysterotomy (whether from a previous classical cesarean, uterine anomaly such as an arcuate or bicornuate uterus, major myomectomy resection, or previous fetal surgery) in active uterine segment. 7. Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal membrane separation, or uterine anomalies. 8. Maternal-fetal Rh alloimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy. 9. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patients HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment. 10. Maternal medical condition that is a contraindication to surgery or anesthesia. 11. Low amniotic fluid volume (Amniotic Fluid Index less than 6 cm) if deemed to be due to fetal anomaly, poor placental perfusion or function, or membrane rupture. Low amniotic fluid volume that responds to maternal hydration is not an exclusion criterion. 12. Patient does not have a support person (i.e. Spouse, partner, mother) available to support the patient for the duration of the pregnancy. 13. Inability to comply with the travel and follow-up requirements of the trial. 14. Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy. 15. Patient scores as severely depressed on the Edinburgh Postnatal Depression Scale 16. Maternal hypersensitivity to collagen. 17. Umbilical Cord hypercoiling or velamentous cord insertion 18. For totally percutaneous expandable port assisted cases: total anterior placentation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neural tube defects are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University: Lucille Packard's Children's Hospital

    Stanford, California, 94305, United States

  • Texas Childrens Hospital

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.